As we step into 2025, we want to take a moment to reflect on all that we achieved together in 2024. It was an incredible year of impact and connection for the Systemic JIA Foundation. We are grateful for each and every one of you – whether you participated in our conferences or donated to a fundraiser, and to our wonderful volunteers who made everything happen.
The 5th NextGen Conference in Washington DC
The fifth NextGen Therapies for SJIA & MAS conference held in November 2024 was the largest ever! 65 attendees joined us in Washington, DC, while many others participated via Zoom. Our heartfelt thanks to the scientists, clinicians, patients, caregiver representatives, FDA/EMA, and pharmaceutical companies who made this conference so fruitful.
The goal of this year’s NextGen Conference (as with NextGen in previous years) was to advance therapies for SJIA, Still’s Disease and MAS.
Videos from NextGen Conference:
All session videos were recorded. Below are links for a few highlights this year. To browse through all sessions, visit our YouTube Playlist for NextGen 2024.
- A comprehensive look at IL18 (measurement, role in disease, IL18-driven clinical trials) (Video 1, Video 2)
- Therapeutic options for refractory patients (Jak-inhibitors & beyond) (Video 3)
- Upcoming clinical trials in SJIA, Still’s & MAS (Video 4)
- Bone Marrow Transplantation for refractory patients (Video 5)
All sessions were recorded and are available to watch anytime:
All sessions were recorded and are available to watch anytime:
Watch all NextGen 2024 YouTube Videos
Want to see how amazing the conference was?
Check out our NextGen 2024 Photo Album
Proceedings Papers were Published in the Pediatric Rheumatology Journal
Scientific publishing is a lengthy process, but we’re proud to share that the proceedings of the 2022 NextGen Conference were finally published in the Pediatric Rheumatology journal as a set of 5 papers. We publish in an open-access journal so that the proceedings are freely accessible to anyone.
- Sinha, R., De Benedetti, F., Grom, A.A. et al. Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13–14, 2022. Pediatr Rheumatol 21 (Suppl 1), 91 (2023).
- Nigrovic, P.A., de Benedetti, F., Kimura, Y. et al. Part 1: The elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still’s disease. Pediatr Rheumatol 21 (Suppl 1), 114 (2023).
- Schulert, G., Vastert, S.J. & Grom, A.A. Part 2: Phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatr Rheumatol 21 (Suppl 1), 87 (2023).
- de Benedetti, F., Grom, A.A. & Brunner, H. Part 3: Clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatr Rheumatol 21 (Suppl 1), 150 (2023).
- Canna, S.W., De Benedetti, F. Part 4: It is time for IL-18 based trials in systemic juvenile idiopathic arthritis?. Pediatr Rheumatol 21 (Suppl 1), 79 (2023).
- Grom, A.A., Canna, S.W., Abu-Arja, R.F. et al. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatr Rheumatol 21 (Suppl 1), 86 (2023).
View Proceedings in Pediatric Rheumatology Journal
The Accelerate Research Project has Enrolled 29 Patients
Thanks to the Rare as One grant from the Chan Zuckerberg Institute, the Systemic JIA Foundation has been working with top researchers at several centers across the USA to understand refractory SJIA in an effort to identify new treatment options.
Currently, we have started working with 8 research centers, including Cincinnati Children’s Hospital Medical Center, Boston Children’s Hospital, The Children’s Hospital of Philadelphia (CHOP), University of Alabama at Birmingham (UAB), University of Minnesota (UMN), Hospital for Special Surgery (HSS), Baylor University and the University of California San Francisco (UCSF). So far, 29 patients have been enrolled and we expect more will be enrolled in 2025.
Scientific Papers We Co-Authored in 2024
The Systemic JIA Foundation takes an active role in partnering with researchers to support and promote research. Sometimes, we help design patient surveys, provide patient perspectives, or help recruit patients for studies. Below is a list of papers published in 2024 from research projects the foundation participated in.
- Fautrel, B., Mitrovic, S., De Matteis, A., et al. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Ann Rheum Dis. 2024;83(12):1614-1627. Published 2024 Nov 14. doi:10.1136/ard-2024-225851
- Baldo, F., Erkens, RGA., E., Mizuta, M., et al. PReS MAS/sJIA Working Party and Paediatric Rheumatology International Trial Organization, Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project, Rheumatology, 2024;, keae391, https://doi.org/10.1093/rheumatology/keae391
- Huang, Y., Sompii-Montgomery, L., Patti, J., et al. Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Arthritis Care Res (Hoboken). 2024 Mar;76(3):328-339. doi: 10.1002/acr.25234. Epub 2023 Nov 27. PMID: 37691306; PMCID: PMC11156420.
- Erkens, RGA., Calis, JJA., Verwoerd, A., et al. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis Rheumatol. 2024;76(1):119-129. doi:10.1002/art.42656
Back to the PReS Conference to Continue Building our European Network
Like 2023, we attended the PReS (or European Paediatric Rheumatology Congress) Conference. For 2024, it was in Gothenburg, Sweden. Our foundation volunteer, Luciana Pereira represented us at the event and connected with physicians, parents, and representatives from other non-profit organizations.
Social Hour for SJIA & Still’s Patients – Rare Disease Day
For Rare Disease Day in 2024, we hosted a virtual Social Hour aimed at raising awareness for rare diseases and supporting Still’s and SJIA patients. The event’s highlight was the two rounds of breakout sessions, where patients shared their experiences. About 55 people registered for the event.
Student Volunteers Presented Poster at World Orphan Drug Congress
In May 2024, at the World Orphan Drug Congress in Boston, a young adult patient, Beatriz Peixoto, along with her colleague, Gabriel Mekis, presented a poster on the emerging option of HSCT for SJIA patients, summarizing a recent paper.
We are inspired by young researchers like Beatriz and Gabriel who are stepping in to help raise awareness about SJIA.
A Huge Thank You to our Donors!
Let’s finish this newsletter with a huge thank you!
We are grateful for the 29 fundraisers started on Facebook for families.
We also want to thank the 37 donors who have donated to our website.
All activities were done with your donations, and each contribution is genuinely appreciated and goes towards research to drive the search for a cure for SJIA. We also included a new stock donation option in 2024.
Your involvement, whether big or small, plays a crucial role in our mission. By joining hands, we’re creating hope and a brighter future for those battling SJIA. Keep supporting us, and let’s continue this journey towards a cure. Thank you for being part of our community and making a positive impact!










Leave a Reply